United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to app… Read more
United Pharm (033270) - Total Liabilities
Latest total liabilities as of September 2025: ₩64.04 Billion KRW
Based on the latest financial reports, United Pharm (033270) has total liabilities worth ₩64.04 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
United Pharm - Total Liabilities Trend (2011–2024)
This chart illustrates how United Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
United Pharm Competitors by Total Liabilities
The table below lists competitors of United Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Qingdao Richen Food Co Ltd
SHG:603755
|
China | CN¥350.17 Million |
|
StealthGas Inc
NASDAQ:GASS
|
USA | $21.36 Million |
|
West Coast Paper Mills Limited
NSE:WSTCSTPAPR
|
India | ₹-40.70 Billion |
|
Sangamo Therapeutics Inc
NASDAQ:SGMO
|
USA | $82.40 Million |
|
Nantong Xingqiu Graphite Co. Ltd. A
SHG:688633
|
China | CN¥1.37 Billion |
|
Zhejiang Xinzhonggang Thermal Power Co Ltd
SHG:605162
|
China | CN¥536.28 Million |
|
Jiangsu Hengshang Energy Conservation Technology Co. Ltd. A
SHG:603137
|
China | CN¥2.09 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down United Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how United Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for United Pharm (2011–2024)
The table below shows the annual total liabilities of United Pharm from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩67.72 Billion | -24.90% |
| 2023-12-31 | ₩90.18 Billion | +12.68% |
| 2022-12-31 | ₩80.03 Billion | +0.90% |
| 2021-12-31 | ₩79.32 Billion | +3.63% |
| 2020-12-31 | ₩76.54 Billion | +0.52% |
| 2019-12-31 | ₩76.14 Billion | +3.64% |
| 2018-12-31 | ₩73.47 Billion | +14.59% |
| 2017-12-31 | ₩64.11 Billion | +12.81% |
| 2016-12-31 | ₩56.83 Billion | +2.84% |
| 2014-12-31 | ₩55.27 Billion | +6.07% |
| 2013-12-31 | ₩52.10 Billion | -3.69% |
| 2012-12-31 | ₩54.10 Billion | -5.16% |
| 2011-12-31 | ₩57.04 Billion | -- |